Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial
Open Access
- 1 September 2019
- journal article
- research article
- Published by Elsevier in The Lancet
- Vol. 394 (10203) , 1011-1021
Abstract
No abstract availableKeywords
Funding Information
- Bill & Melinda Gates Foundation (OPP1017337)
This publication has 15 references indexed in Scilit:
- Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trialBJOG: An International Journal of Obstetrics & Gynaecology, 2015
- Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy: Executive SummaryJournal of Obstetrics and Gynaecology Canada, 2014
- Moving beyond essential interventions for reduction of maternal mortality (the WHO Multicountry Survey on Maternal and Newborn Health): a cross-sectional studyThe Lancet, 2013
- Pharmacotherapy for Preeclampsia in Low and Middle Income Countries: An Analysis of Essential Medicines ListsJournal of Obstetrics and Gynaecology Canada, 2013
- Outcomes of severe pre‐eclampsia/eclampsia in Yorkshire 1999/2003BJOG: An International Journal of Obstetrics & Gynaecology, 2005
- Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancyAmerican Journal of Obstetrics and Gynecology, 2002
- Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trialThe Lancet, 2002
- Too far to walk: Maternal mortality in contextSocial Science & Medicine, 1994
- Ketanserin Versus α-Methyldopa in the Treatment of Hypertension During PregnancyJournal of Cardiovascular Pharmacology, 1987
- Ketanserin Versus α-Methyldopa in the Treatment of Hypertension During PregnancyJournal of Cardiovascular Pharmacology, 1987